Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced between $2.3 million - $3.9 million.
The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (Orchard Therapeutics) for metachromatic leukodystrophy.
